Abstract
The last several years have seen major progress towards the goal of translating our growing understanding of the molecular basis of cancer into drugs with improved therapeutic activity and selectivity. Tremendous advances have been made but significant obstacles remain. In this review we assess our experience in the design and development of signal transduction drugs for cancer treatment, with a specific focus on small molecule kinase inhibitors. The druggability of cancer kinome targets is exemplified by imatinib, gefitinib, erlotinib and many other emerging agents. We assess the current status of the design of potent and selective kinase inhibitors, which has benefited greatly from high throughput screening and structure-based approaches. A diverse range of kinase inhibitory scaffolds is now available based on these methods. Multi-parameter optimisation now focuses as much on pharmacokinetic and metabolic properties as it does on target potency and selectivity. Development of a molecular audit trail requiring assays to demonstrate mechanism of action in vitro and in vivo is essential. Current issues include our relatively poor ability to predict the level of kinase selectivity in the intact cell, uncertainties around the most desirable selectivity profile, and the emergence of drug resistance.
Keywords: Cancer, kinase, inhibitor, structure-based design, selectivity, pharmacodynamics
Current Signal Transduction Therapy
Title: Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets
Volume: 1 Issue: 1
Author(s): Ian Collins and Paul Workman
Affiliation:
Keywords: Cancer, kinase, inhibitor, structure-based design, selectivity, pharmacodynamics
Abstract: The last several years have seen major progress towards the goal of translating our growing understanding of the molecular basis of cancer into drugs with improved therapeutic activity and selectivity. Tremendous advances have been made but significant obstacles remain. In this review we assess our experience in the design and development of signal transduction drugs for cancer treatment, with a specific focus on small molecule kinase inhibitors. The druggability of cancer kinome targets is exemplified by imatinib, gefitinib, erlotinib and many other emerging agents. We assess the current status of the design of potent and selective kinase inhibitors, which has benefited greatly from high throughput screening and structure-based approaches. A diverse range of kinase inhibitory scaffolds is now available based on these methods. Multi-parameter optimisation now focuses as much on pharmacokinetic and metabolic properties as it does on target potency and selectivity. Development of a molecular audit trail requiring assays to demonstrate mechanism of action in vitro and in vivo is essential. Current issues include our relatively poor ability to predict the level of kinase selectivity in the intact cell, uncertainties around the most desirable selectivity profile, and the emergence of drug resistance.
Export Options
About this article
Cite this article as:
Collins Ian and Workman Paul, Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269181
DOI https://dx.doi.org/10.2174/157436206775269181 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy for Ischemic Brain Diseases
Current Gene Therapy Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy Gene Expression Profiles Induced by Amphetamine and Phencyclidine; Novel Targets for the Treatment of Drug Psychosis and Schizophrenia
Medicinal Chemistry Reviews - Online (Discontinued) Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets Raloxifene: Cardiovascular Considerations
Mini-Reviews in Medicinal Chemistry Apoptosis in Sepsis: Mechanisms, Clinical Impact and Potential Therapeutic Targets
Current Pharmaceutical Design Establishment of Conditionally Immortalized Cell Lines with Specific Functions and its Application to Differential Gene Expression Analysis by DNA Microarray Technology
Current Pharmaceutical Analysis Protein Geranylgeranyltransferase Type 1 as a Target in Cancer
Current Cancer Drug Targets The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
Current Gene Therapy Biochemical Mechanisms of Cisplatin Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry Role of Microtubules Network in CYP Genes Expression
Current Drug Metabolism Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Pathobiology of Head and Neck Squamous Tumorigenesis
Current Cancer Drug Targets An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery